12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Somatoprim: Phase IIa started

Aspireo began an open-label, Ukrainian Phase IIa trial to evaluate single ascending-doses of 100, 300, 900 and 1,800 µg subcutaneous Somatoprim in combination with 300 µg octreotide in up to 20 untreated acromegaly patients.

The compound was...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >